Loading people...
Geert-Jan Mulder is a co-founding Managing Partner at the life sciences venture capital firm Forbion, based in Naarden, Netherlands. He earned his Medical Degree from the University of Utrecht and practiced obstetrics and gynecology before transitioning to the pharmaceutical industry with roles at Searle and Byk Gulden. Mulder entered venture capital in 2001 as an Investment Director at ABN AMRO Capital Life Sciences, spinning out the team to establish Forbion in 2006. The firm now manages over €3 billion in assets, recently closing its €890 million Forbion Ventures VII fund in October 2024. He has directed biotechnology investments resulting in notable exits, including PanGenetics to Abbott, Acerta Pharma to AstraZeneca, and the 2013 Nasdaq IPO of bluebird bio. Mulder currently focuses on guiding clinical-stage therapeutics companies through complex regulatory filings and pharmaceutical development strategies.
Geert-Jan Mulder stands as a pivotal figure in the European life sciences venture capital landscape, serving as a co-founder and Managing Partner at Forbion. Forbion is renowned for its strategic investments in groundbreaking life sciences companies, and Geert-Jan's leadership has been instrumental in shaping its success and impact on global healthcare innovation.
In his role as Managing Partner, Geert-Jan Mulder is deeply involved in all aspects of Forbion's investment strategy, from identifying promising early-stage opportunities to guiding growth-stage companies towards significant milestones and successful exits. His investment focus is sharply honed on the life sciences sector, encompassing innovative biotech, pharmaceutical, and medical device companies. He seeks out ventures developing novel therapeutics, particularly in areas with high unmet medical needs, such as oncology, immunology, rare diseases, and central nervous system disorders. His approach is characterized by a blend of rigorous scientific due diligence and astute business acumen, ensuring that Forbion backs companies with strong scientific foundations and clear paths to market.
Geert-Jan's distinguished career background provides a robust foundation for his investment decisions. He holds a PhD in Molecular Biology from Leiden University and completed a postdoctoral fellowship at MIT, giving him a profound understanding of the scientific intricacies of the biotech world. Prior to co-founding Forbion in 2006, he honed his investment expertise as a partner at ABN AMRO Capital Life Sciences, where he gained extensive experience in venture capital and private equity within the healthcare sector. This unique combination of deep scientific knowledge and seasoned investment experience allows him to effectively evaluate complex scientific propositions and translate them into viable investment opportunities.
Throughout his tenure at Forbion, Geert-Jan Mulder has been involved in numerous successful investments that have brought significant value to patients and investors alike. Notable examples include his involvement with companies like Acerta Pharma, which was acquired by AstraZeneca for up to $7 billion, and Dezima Pharma, acquired by Amgen for up to $1.55 billion. These successes underscore his ability to identify and nurture companies with the potential for transformative impact. His contributions extend beyond capital, often involving active participation on company boards, providing strategic guidance, and leveraging his extensive network to accelerate growth and development. Geert-Jan Mulder continues to be a driving force behind Forbion's mission to build leading life sciences companies that deliver innovative medicines to patients worldwide.
Geert-Jan Mulder primarily invests in early-stage and growth-stage life sciences companies. His focus areas include innovative biotech, pharmaceutical, and medical device companies developing novel therapeutics, particularly in areas with high unmet medical needs.
Geert-Jan Mulder works as a Managing Partner at Forbion, a European venture capital firm with offices in Naarden, The Netherlands, and Munich, Germany.
